These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34144488)

  • 1. Olaparib enhances curcumin-mediated apoptosis in oral cancer cells by inducing PARP trapping through modulation of BER and chromatin assembly.
    Molla S; Chatterjee S; Sethy C; Sinha S; Kundu CN
    DNA Repair (Amst); 2021 Sep; 105():103157. PubMed ID: 34144488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade.
    Molla S; Hembram KC; Chatterjee S; Nayak D; Sethy C; Pradhan R; Kundu CN
    Pathol Oncol Res; 2020 Oct; 26(4):2091-2103. PubMed ID: 31768967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping.
    Chatterjee S; Dhal AK; Paul S; Sinha S; Das B; Dash SR; Kundu CN
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3521-3535. PubMed ID: 35962813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells.
    Sethy C; Kundu CN
    Toxicol Appl Pharmacol; 2022 Feb; 436():115860. PubMed ID: 34998856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Talazoparib enhances the quinacrine-mediated apoptosis in patient-derived oral mucosa CSCs by inhibiting BER pathway through the modulation of GCN5 and P300.
    Das C; Dash SR; Sinha S; Paul S; Das B; Bhal S; Sethy C; Kundu CN
    Med Oncol; 2023 Nov; 40(12):351. PubMed ID: 37940725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib enhances the Resveratrol-mediated apoptosis in breast cancer cells by inhibiting the homologous recombination repair pathway.
    Sinha S; Chatterjee S; Paul S; Das B; Dash SR; Das C; Kundu CN
    Exp Cell Res; 2022 Nov; 420(1):113338. PubMed ID: 36075449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Resveratrol and PARP inhibitor Olaparib efficiently deregulates homologous recombination repair pathway in breast cancer cells through inhibition of TIP60-mediated chromatin relaxation.
    Sinha S; Paul S; Acharya SS; Das C; Dash SR; Bhal S; Pradhan R; Das B; Kundu CN
    Med Oncol; 2024 Jan; 41(2):49. PubMed ID: 38184505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli.
    Siddharth S; Nayak D; Nayak A; Das S; Kundu CN
    DNA Repair (Amst); 2016 Sep; 45():44-55. PubMed ID: 27334689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
    Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair.
    Tsuda M; Cho K; Ooka M; Shimizu N; Watanabe R; Yasui A; Nakazawa Y; Ogi T; Harada H; Agama K; Nakamura J; Asada R; Fujiike H; Sakuma T; Yamamoto T; Murai J; Hiraoka M; Koike K; Pommier Y; Takeda S; Hirota K
    PLoS One; 2017; 12(11):e0188320. PubMed ID: 29149203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
    Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
    Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
    Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
    J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP-1/2 Inhibitor Olaparib Prevents or Partially Reverts EMT Induced by TGF-β in NMuMG Cells.
    Schacke M; Kumar J; Colwell N; Hermanson K; Folle GA; Nechaev S; Dhasarathy A; Lafon-Hughes L
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors.
    Perini V; Schacke M; Liddle P; Vilchez-Larrea S; Keszenman DJ; Lafon-Hughes L
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p21CDKN1A Regulates the Binding of Poly(ADP-Ribose) Polymerase-1 to DNA Repair Intermediates.
    Dutto I; Sukhanova M; Tillhon M; Cazzalini O; Stivala LA; Scovassi AI; Lavrik O; Prosperi E
    PLoS One; 2016; 11(1):e0146031. PubMed ID: 26730949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
    Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment.
    Juhász S; Smith R; Schauer T; Spekhardt D; Mamar H; Zentout S; Chapuis C; Huet S; Timinszky G
    Sci Adv; 2020 Dec; 6(51):. PubMed ID: 33355125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.